This message is intended for sites in the process of receiving approval from the DAIDS Office of Clinical Site Oversight (OCSO) to participate in REPRIEVE (A5332).
Randomized Trial to Prevent Vascular Events in HIV – REPRIEVE (A5332)
Dear Site Staff,
Thank you for your participation in the REPRIEVE (A5332) trial. We look forward to working with you. We have scheduled two 90-minute start-up calls for REPRIEVE (A5332) this month: February 13 at 3 PM EST and February 16 at 10 am EST. The agenda is the same so you do not have to attend both calls. We realize that February 16 is a holiday for some but it works for many, and there will be other opportunities for training.
The calls are open to all at your site but the target audience is site PIs, coordinators, research nurses, site pharmacists, and lab staff. Your collaborating cardiologist is also welcome. Please note that there will be separate data management training for REPRIEVE, which will include information on user accounts, subject enrollment, case report forms and schedules, and OpenClinica (the clinical trials data management system to be used for this trial).
The final agenda and a slide deck will be distributed prior to each call. If you have any questions about these trainings or the REPRIEVE trial, please send them to email@example.com.
REPRIEVE (A5332) Startup Calls have been scheduled for:
Friday, February 13, 2015 at:
3:00 PM EST
2:00 PM CST
1:00 PM MST
12:00 NOON PST
Monday, February 16, 2015 at:
10:00 AM EST
9:00 AM CST
8:00 AM MST
7:00 AM PST
For both calls:
US & Canada Toll Free #: 1-800-504-8071
Access Code: 62 227 98#
Call Host: Barbara Bastow
Dial-In Time: 10 minutes prior to call